Alnylam Pharmaceuticals
ALNY
#590
Rank
A$51.07 B
Marketcap
$397.87
Share price
1.35%
Change (1 day)
21.19%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : A$1.95 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is A$1.95 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$1.91 B-1.24%
2022-12-31A$1.94 B41.41%
2021-12-31A$1.37 B102.85%
2020-12-31A$0.67 B56.49%
2019-12-31A$0.43 B915.28%
2018-12-31A$42.57 M10.78%
2017-12-31A$38.42 M-81.53%
2016-12-31A$0.20 B
2007-12-31A$7.73 M-33.27%
2006-12-31A$11.58 M14.67%
2005-12-31A$10.1 M8.61%
2004-12-31A$9.3 M272.07%
2003-12-31A$2.5 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
A$0.17 B-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
A$4.05 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
A$2.05 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.40 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
A$2.11 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
A$43.47 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$38.18 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
A$28.38 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel